Dublin, April 09, 2019 (GLOBE NEWSWIRE) -- The "Global Antiretroviral Drugs Market: Analysis By Drug Type, By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast (2013-2023)" report has been added to ResearchAndMarkets.com's offering. Global antiretroviral market is projected to display a robust growth represented by a CAGR of 4.70% during 2018-2023 Over the recent years, Antiretroviral drugs market has been witnessing growth on account of several driving factors including growing prevalence of HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficacy. Moreover, factors such as growing medical spending, favorable steps by government of various countries, decreased cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population has been driving the market growth of antiretroviral drugs. In addition, increasing uptake of INSTI based regimens, increasing awareness regarding HIV care and treatment procedures, new drug launches, and improved R&D pipeline are anticipated to fuel the market growth in forecasted period. However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth. In this research report, the market is segmented on the basis of drug type. By drug type, the multi-class drug combinations are predicted to hold their dominant position in the market, especially Gilead Sciences product Biktarvy and ViiV Healthcare product Triumeq are expected to give more traction to the market. Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017. The largest share of North America is attributed to high ART coverage rate and more emphasis towards prescribed branded drugs. Key Topics Covered: 1. Research Methodology 2. Executive Summary 3. Strategic Recommendations 4. Antiretroviral Drugs Products Outlook 5. Global Antiretroviral Drugs Market: Growth and Forecast 5.1 By Value (2013-2017) 5.2 By Value (2018-2023) 6. Global Antiretroviral Drugs Market: Segment Analysis 6.1 Global Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%) 6.2 Global Multi-Class Drugs Combination Market Size, By Value (2013-2023) 6.3 Global NRTI Market Size, By Value (2013-2023) 6.4 Global NNRTI Market Size, By Value (2013-2023) 6.5 Global Protease Inhibitors Market Size, By Value (2013-2023) 6.6 Global Other Antiretroviral Drugs Market Size, By Value (2013-2023) 6.6 Global Antiretroviral Drugs: Market Attractiveness, By Drug Type 6.7 Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5) 7. Global Antiretroviral Drugs Market: Regional Analysis 7.1 Global Antiretroviral Drugs Market Size, By Region: Breakdown (%) 7.1.1 Global Antiretroviral Drugs Market Size, By Region, 2017 (%) 7.1.2 Global Antiretroviral Drugs Market Size, By Region, 2023 (%) 8. North America Antiretroviral Drugs Market: Growth and Forecast 9. Europe Antiretroviral Drugs Market: Growth and Forecast 10. APAC Antiretroviral Drugs Market: Growth and Forecast 11. ROW Antiretroviral Drugs Market: Growth and Forecast 12. Global Antiretroviral Drugs Market: Market Dynamics 12.1 Global Antiretroviral Drugs Market: Drivers 12.2 Global Antiretroviral Drugs Market: Restrains 12.3 Global Antiretroviral Drugs Market: Trends 12.4 Global Antiretroviral Drugs Market: Product Benchmarking 13. Porter Five Force Analysis 14. SWOT Analysis 15. Company Profiles

  • Gilead Sciences Inc.
  • ViiV Healthcare
  • Bristol-Myers Squibb
  • AbbVie Inc.
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Merck & Co.
  • Cipla
  • Mylan

For more information about this report visit https://www.researchandmarkets.com/r/yapm48

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900